|Articles|February 28, 2023

Parexel Introduces Expert Series—New Medicines, Novel Insights

Parexel has announced the launch of a new expert series, New Medicines, Novel Insights. The series will feature insights from the company’s global, cross-functional experts analyzing trends impacting drug development and offering evidence-based guidance to the biopharmaceutical industry.

The inaugural report—Advancing Rare Disease Drug Development—explores the unique regulatory, scientific, and market access challenges surrounding rare disease drug development and shares best practices to address them.

To view the full New Medicines, Novel Insights: Advancing Rare Disease Drug Development report and subscribe to receive future reports, visit the interactive experience.

Reference

Parexel Introduces Expert Series – New Medicines, Novel Insights. (2023, February 28). GlobeNewswire.


Related to this article

© C Davids/peopleimages.com - © C Davids/peopleimages.com - stock.adobe.com
The clinical research industry talks about patient-centeredness constantly but embeds it too late, too narrowly, and without clear ownership, and the cost shows up in enrollment failures, protocol deviations, and outcomes that don't reflect what patients actually care about.
The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.